-
1
-
-
79251470391
-
Projections of the cost of cancer care in the United States: 2010-2020
-
Mariotto AB, Yabroff KR, Shao Y, et al: Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 103:117-128, 2011
-
(2011)
J Natl Cancer Inst
, vol.103
, pp. 117-128
-
-
Mariotto, A.B.1
Yabroff, K.R.2
Shao, Y.3
-
3
-
-
84890150950
-
Access, affordability, and insurance complexity are often worse in the United States compared to 10 other countries
-
Schoen C, Osborn R, Squires D, et al: Access, affordability, and insurance complexity are often worse in the United States compared to 10 other countries. Health Aff (Millwood) 32:2205-2215, 2013
-
(2013)
Health Aff (Millwood)
, vol.32
, pp. 2205-2215
-
-
Schoen, C.1
Osborn, R.2
Squires, D.3
-
5
-
-
84891686782
-
Delivering high-quality and affordable care throughout the cancer care continuum
-
Shih YT, Ganz PA, Aberle D, et al: Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol 31:4151-4157, 2013
-
(2013)
J Clin Oncol
, vol.31
, pp. 4151-4157
-
-
Shih, Y.T.1
Ganz, P.A.2
Aberle, D.3
-
6
-
-
84867828250
-
Patients' expectations about effects of chemotherapy for advanced cancer
-
Weeks JC, Catalano PJ, Cronin A, et al: Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med 367:1616-1625, 2012
-
(2012)
N Engl J Med
, vol.367
, pp. 1616-1625
-
-
Weeks, J.C.1
Catalano, P.J.2
Cronin, A.3
-
7
-
-
84879256683
-
Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis
-
Ramsey S, Blough D, Kirchhoff A, et al: Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood) 32:1143-1152, 2013
-
(2013)
Health Aff (Millwood)
, vol.32
, pp. 1143-1152
-
-
Ramsey, S.1
Blough, D.2
Kirchhoff, A.3
-
8
-
-
84876486250
-
Financial toxicity, part 1: A new name for a growing problem
-
Zafar SY, Abernathy AP: Financial toxicity, part 1: A new name for a growing problem. Oncology (Williston Park) 27:80-81, 149, 2013
-
(2013)
Oncology (Williston Park)
, vol.27
-
-
Zafar, S.Y.1
Abernathy, A.P.2
-
9
-
-
80052695744
-
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions
-
Streeter SB, Schwartzberg L, Husain N, et al: Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. J Oncol Pract 7:46s-51s, 2011 (suppl)
-
(2011)
J Oncol Pract
, vol.7
, pp. 46s-51s
-
-
Streeter, S.B.1
Schwartzberg, L.2
Husain, N.3
-
10
-
-
84925333002
-
Population-based assessment of cancer survivors' financial burden and quality of life: A prospective cohort study
-
Zafar SU, McNeil RB, Thomas CM, et al: Population-based assessment of cancer survivors' financial burden and quality of life: A prospective cohort study. J Oncol Pract 11:145-150, 2015
-
(2015)
J Oncol Pract
, vol.11
, pp. 145-150
-
-
Zafar, S.U.1
McNeil, R.B.2
Thomas, C.M.3
-
11
-
-
84874631714
-
The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient's experience
-
Zafar SY, Peppercorn JM, Schrag D, et al: The financial toxicity of cancer treatment: A pilot study assessing out-of-pocket expenses and the insured cancer patient's experience. Oncologist 18:381-390, 2013
-
(2013)
Oncologist
, vol.18
, pp. 381-390
-
-
Zafar, S.Y.1
Peppercorn, J.M.2
Schrag, D.3
-
12
-
-
84940531023
-
Provider-patient communication about cost of care: Results from a national patient education program
-
Ahmed IA, Harvey A, Amsellem M, et al: Provider-patient communication about cost of care: Results from a national patient education program. J Clin Oncol 31:594s, 2013 (suppl 15; abstr 9578)
-
(2013)
J Clin Oncol
, vol.31
, pp. 594s
-
-
Ahmed, I.A.1
Harvey, A.2
Amsellem, M.3
-
13
-
-
0042697034
-
Patient-physician communication about out-of-pocket costs
-
Alexander GC, Casalino LP, Meltzer DO: Patient-physician communication about out-of-pocket costs. JAMA 290:953-958, 2003
-
(2003)
JAMA
, vol.290
, pp. 953-958
-
-
Alexander, G.C.1
Casalino, L.P.2
Meltzer, D.O.3
-
14
-
-
84919769081
-
Debating the oncologist's role in defining the value of cancer care: Our duty is to our patients
-
Sulmasy D, Moy B: Debating the oncologist's role in defining the value of cancer care: Our duty is to our patients. J Clin Oncol 32:4039-4041, 2014
-
(2014)
J Clin Oncol
, vol.32
, pp. 4039-4041
-
-
Sulmasy, D.1
Moy, B.2
-
15
-
-
0034890949
-
Should physicians be gatekeepers of medical resources?
-
Weinstein MC: Should physicians be gatekeepers of medical resources? J Med Ethics 27:268-274, 2001
-
(2001)
J Med Ethics
, vol.27
, pp. 268-274
-
-
Weinstein, M.C.1
-
16
-
-
68949112230
-
American Society of Clinical Oncology guidance statement: The cost of cancer care
-
Meropol NJ, Schrag D, Smith TJ, et al: American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 27:3868-3874, 2009
-
(2009)
J Clin Oncol
, vol.27
, pp. 3868-3874
-
-
Meropol, N.J.1
Schrag, D.2
Smith, T.J.3
-
17
-
-
84863195517
-
ASCO identifies five key opportunities to improve care and reduce costs: The top five list for oncology
-
Schnipper LE, Smith TJ, Raghavan D, et al: ASCO identifies five key opportunities to improve care and reduce costs: The top five list for oncology. J Clin Oncol 30:1715-1724, 2012
-
(2012)
J Clin Oncol
, vol.30
, pp. 1715-1724
-
-
Schnipper, L.E.1
Smith, T.J.2
Raghavan, D.3
-
18
-
-
84892900404
-
American Society of Clinical Oncology 2013 top five list in oncology
-
Schnipper LE, Lyman GH, Blayney DW: American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol 31:4362-4370, 2013
-
(2013)
J Clin Oncol
, vol.31
, pp. 4362-4370
-
-
Schnipper, L.E.1
Lyman, G.H.2
Blayney, D.W.3
-
19
-
-
84855264223
-
Review of the American College of Physicians Ethics Manual: Sixth edition
-
Snyder LS: Review of the American College of Physicians Ethics Manual: Sixth edition. Ann Intern Med 156:73-104, 2012
-
(2012)
Ann Intern Med
, vol.156
, pp. 73-104
-
-
Snyder, L.S.1
-
20
-
-
78649948668
-
A method for defining value in healthcare using cancer care as a model
-
Feeley TW, Fly HS, Albright H, et al: A method for defining value in healthcare using cancer care as a model. J Healthc Manag 55:399-411, 2010
-
(2010)
J Healthc Manag
, vol.55
, pp. 399-411
-
-
Feeley, T.W.1
Fly, H.S.2
Albright, H.3
-
23
-
-
58149092838
-
Decision making and quality of life in the treatment of cancer: A review
-
Zafar SY, Alexander SC, Weinfurt KP, et al: Decision making and quality of life in the treatment of cancer: A review. Support Care Cancer 17:117-127, 2009
-
(2009)
Support Care Cancer
, vol.17
, pp. 117-127
-
-
Zafar, S.Y.1
Alexander, S.C.2
Weinfurt, K.P.3
-
24
-
-
77954636785
-
Beyond costs and benefits: Understanding how patients make health care decisions
-
Ubel PA: Beyond costs and benefits: Understanding how patients make health care decisions. Oncologist 15:5-10, 2010 (suppl 1)
-
(2010)
Oncologist
, vol.15
, pp. 5-10
-
-
Ubel, P.A.1
-
25
-
-
77953660030
-
Drug pricing and value in oncology
-
Danzon PM, Taylor E: Drug pricing and value in oncology. Oncologist 15:24-31, 2010 (suppl 1)
-
(2010)
Oncologist
, vol.15
, pp. 24-31
-
-
Danzon, P.M.1
Taylor, E.2
-
26
-
-
33745959588
-
Communication preferences and needs of cancer patients: The importance of content
-
Surbone A: Communication preferences and needs of cancer patients: The importance of content. Support Care Cancer 14:789-791, 2006
-
(2006)
Support Care Cancer
, vol.14
, pp. 789-791
-
-
Surbone, A.1
-
29
-
-
33645662113
-
Centralized drug review processes in Australia, Canada, New Zealand, and the United Kingdom
-
Morgan SG, McMahon M, Mitton C, et al: Centralized drug review processes in Australia, Canada, New Zealand, and the United Kingdom. Health Aff (Millwood) 25:337-347, 2006
-
(2006)
Health Aff (Millwood)
, vol.25
, pp. 337-347
-
-
Morgan, S.G.1
McMahon, M.2
Mitton, C.3
-
31
-
-
84940546318
-
-
Scottish Medicines Consortium: Templates/guidelines for submission. https://www.scottishmedicines.org.uk/Submission-Process/Submission-guidance-and-forms/Templates-Guidance-for-Submission/Templates-Guidance-for-Submission
-
Templates/guidelines for Submission
-
-
-
32
-
-
84940498675
-
-
All Wales Medicines Strategy Group: Medicines strategy for Wales. http://www.awmsg.org/awmsg-strategy.html
-
Medicines Strategy for Wales
-
-
-
39
-
-
84896706532
-
Does comparative effectiveness research promote rationing of cancer care?
-
Peppercorn J, Zafar SY, Houck K, et al: Does comparative effectiveness research promote rationing of cancer care? Lancet Oncol. 15:e132-e138, 2014
-
(2014)
Lancet Oncol
, vol.15
, pp. e132-e138
-
-
Peppercorn, J.1
Zafar, S.Y.2
Houck, K.3
-
40
-
-
84901630147
-
ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: A report of the American College of Cardiology/American Heart Association task force on performance measures and task force on practice guidelines
-
Anderson JL, Heidenreich PA, Barnett PG, et al: ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: A report of the American College of Cardiology/American Heart Association task force on performance measures and task force on practice guidelines. J Am Coll Cardiol 63:2304-2322, 2014
-
(2014)
J Am Coll Cardiol
, vol.63
, pp. 2304-2322
-
-
Anderson, J.L.1
Heidenreich, P.A.2
Barnett, P.G.3
-
41
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-50, 2006
-
(2006)
N Engl J Med
, vol.355
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
-
42
-
-
49049089802
-
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer
-
Scagliotti GV, Parikh P, von Pawel J, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543-3551, 2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 3543-3551
-
-
Scagliotti, G.V.1
Parikh, P.2
Von Pawel, J.3
-
43
-
-
0035849269
-
Platinum-based and nonplatinum-based chemotherapy in advanced non-small-cell lung cancer: A randomized multicenter trial
-
Georgoulias V, Papadakis E, Alexopoulos A, et al: Platinum-based and nonplatinum-based chemotherapy in advanced non-small-cell lung cancer: A randomized multicenter trial. Lancet 357:1478-1484, 2001
-
(2001)
Lancet
, vol.357
, pp. 1478-1484
-
-
Georgoulias, V.1
Papadakis, E.2
Alexopoulos, A.3
-
44
-
-
84857502654
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicenter, open-label, randomized phase 3 trial
-
Rosell R, Carcereny E, Gervais R, et al: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicenter, open-label, randomized phase 3 trial. Lancet Oncol 13:239-246, 2012
-
(2012)
Lancet Oncol
, vol.13
, pp. 239-246
-
-
Rosell, R.1
Carcereny, E.2
Gervais, R.3
-
45
-
-
84940500451
-
-
UnitedHealthcare
-
UnitedHealthcare
-
-
-
-
46
-
-
50449086728
-
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
-
San Miguel JF, Schlag R, Khuageva NK, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917, 2008
-
(2008)
N Engl J Med
, vol.359
, pp. 906-917
-
-
San Miguel, J.F.1
Schlag, R.2
Khuageva, N.K.3
-
47
-
-
84874768399
-
Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma
-
San Miguel JF, Schlag R, Khuageva NK, et al: Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 31:448-455, 2013
-
(2013)
J Clin Oncol
, vol.31
, pp. 448-455
-
-
San Miguel, J.F.1
Schlag, R.2
Khuageva, N.K.3
-
48
-
-
79957443342
-
Abiraterone and increased survival in metastatic prostate cancer
-
De Bono JS, Logothetis CJ, Molina A, et al: Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005, 2011
-
(2011)
N Engl J Med
, vol.364
, pp. 1995-2005
-
-
De Bono, J.S.1
Logothetis, C.J.2
Molina, A.3
-
49
-
-
84870243969
-
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: Exploratory analysis of data from the COU-AA-301 randomized trial
-
Logothetis CJ, Basch E, Molina A, et al: Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: Exploratory analysis of data from the COU-AA-301 randomized trial. Lancet Oncol 13:1210-1217, 2012
-
(2012)
Lancet Oncol
, vol.13
, pp. 1210-1217
-
-
Logothetis, C.J.1
Basch, E.2
Molina, A.3
-
50
-
-
77957682309
-
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial
-
De Bono JS, Oudard S, Ozguroglu M, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial. Lancet 376:1147-1154, 2010
-
(2010)
Lancet
, vol.376
, pp. 1147-1154
-
-
De Bono, J.S.1
Oudard, S.2
Ozguroglu, M.3
-
51
-
-
84866770294
-
Increased survival with enzalutamide in prostate cancer after chemotherapy
-
Scher HI, Fizazi K, Saad F, et al: Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197, 2012
-
(2012)
N Engl J Med
, vol.367
, pp. 1187-1197
-
-
Scher, H.I.1
Fizazi, K.2
Saad, F.3
-
52
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
-
(2005)
N Engl J Med
, vol.353
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
-
53
-
-
80052728749
-
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31
-
Perez EA, Romond EH, Suman VJ, et al: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366-3373, 2011
-
(2011)
J Clin Oncol
, vol.29
, pp. 3366-3373
-
-
Perez, E.A.1
Romond, E.H.2
Suman, V.J.3
-
54
-
-
80053539103
-
Adjuvant trastuzumab in HER2-positive breast cancer
-
Slamon D, Eirmann W, Robert N, et al: Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365:1273-1283, 2011
-
(2011)
N Engl J Med
, vol.365
, pp. 1273-1283
-
-
Slamon, D.1
Eirmann, W.2
Robert, N.3
-
55
-
-
84899911233
-
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes
-
Ellis LM, Bernstein DS, Voest EE, et al: American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 32:1277-1280, 2014
-
(2014)
J Clin Oncol
, vol.32
, pp. 1277-1280
-
-
Ellis, L.M.1
Bernstein, D.S.2
Voest, E.E.3
-
56
-
-
0031900689
-
Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis
-
Stinnett AA, Mullahy J: Net health benefits: A new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 12:S68-S80, 1998 (suppl)
-
(1998)
Med Decis Making
, vol.12
, pp. S68-S80
-
-
Stinnett, A.A.1
Mullahy, J.2
-
58
-
-
2442562971
-
Problems and solutions in calculating quality-adjusted life years (QALYs)
-
Prieto L, Sacristán JA: Problems and solutions in calculating quality-adjusted life years (QALYs). Health Qual Life Outcomes 1:80, 2003
-
(2003)
Health Qual Life Outcomes
, vol.1
, pp. 80
-
-
Prieto, L.1
Sacristán, J.A.2
|